MetaCap

4D Molecular Therapeutics (FDMT) vs Iambic Therapeutics (IAM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Iambic Therapeutics is the larger company by market cap ($621.4 million vs $576.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FDMT-20.51%IAM-30.67%
+30%-10%-50%
Oct 15, 20261 yearNov 20, 2026
FDMT-15.73%IAM-44.94%
+4%-28%-60%
Oct 12, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FDMT versus IAM key metrics
MetricFDMTIAM
Share price$10.23$13.11
Market cap$576.76M$621.42M
1-day change-4.57%-8.06%
YTD return+36.40%—
1-year return-5.63%—
5-year return-53.61%—
EPS (TTM)$-2.70$-2.69
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$85.21M—
Revenue growth (YoY)+230194.59%—
Net income (latest FY)$-140.11M—
Operating margin-187.24%—
Net margin-164.43%—
52-week high$16.93$25.00
52-week low$6.96$9.60
Distance from 52-week high-39.57%-47.56%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+174.58%+107.86%
Average volume967.00K714.92K
Shares outstanding56.38M47.40M
Employees196171
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About 4D Molecular Therapeutics

FDMT stock →

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees

About Iambic Therapeutics

IAM stock →

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 171 employees

FDMT vs IAM FAQ

Which is bigger, 4D Molecular Therapeutics or Iambic Therapeutics?

Iambic Therapeutics (IAM) is larger, with a market capitalization of $621.42M compared with $576.76M for 4D Molecular Therapeutics (FDMT).

Are 4D Molecular Therapeutics and Iambic Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons